# MOTS-c

> MOTS-c is a mitochondrial-derived peptide encoded by a short open reading frame within mitochondrial DNA. Preclinical research suggests it may influence energy metabolism and insulin sensitivity through activation of the AMPK signaling pathway. Human clinical trial data remain very limited, and most available evidence comes from animal and cell-culture studies. It is considered an emerging research compound rather than an established weight-management therapy.

- URL: https://www.lifeconverted.com/peptides/mots-c
- Primary category: Weight Management
- Effectiveness rank: #26 in Weight Management; #4 in Immune & Anti-Aging; #2 in Metabolic
- Evidence level: Emerging research
- Route: Subcutaneous
- Dose range: 5-10 mg
- Dose tiers: low 5 mg; moderate 10 mg; high 10 mg
- Half-life: Not well characterized in humans; preclinical data suggest a short half-life on the order of minutes to a few hours
- Timing: ~30 min before a workout
- Cycle: Research protocols commonly reference cycles of 8-12 weeks on, 4 weeks or more between cycles in informal research protocols off (No standardized cycle length has been established in peer-reviewed human research.)
- Storage: Reconstituted peptide should be refrigerated at 2-8°C, protected from light, and used within the manufacturer's or compounding pharmacy's stated timeframe; lyophilized powder is typically stored frozen or refrigerated before reconstitution.

## Mechanism of action

MOTS-c is proposed to translocate to the nucleus under metabolic stress and regulate gene expression related to energy metabolism, partly through activation of AMPK (AMP-activated protein kinase). AMPK activation is associated with increased glucose uptake and fatty acid oxidation in preclinical models, which is the basis for interest in its potential metabolic and weight-related effects in humans.

## Reported benefits

- May support insulin sensitivity based on preclinical research
- Proposed role in mitochondrial energy metabolism
- Investigated for potential effects on exercise capacity in animal studies
- Distinct mechanism (AMPK pathway) from incretin-based weight agents

## Reported side effects

- Injection-site reactions
- Limited human safety data; adverse effect profile not well characterized
- Potential for unknown effects given the short duration of most existing research
- Theoretical risk of interactions with metabolic conditions or medications, not yet studied

## Common protocols

- Informal research protocols using subcutaneous injection 2-3 times weekly for 8-12 week cycles

## Stacking notes

Sometimes discussed alongside other metabolic-research peptides; no controlled human data support or refute combination use.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer